Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US

BACKGROUND: Free-dose combination treatment with basal insulin and short-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduces hyperglycemia via complementary targeting of fasting and postprandial blood glucose levels, however, in the real world, due to injection burden and clinical i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jay, Lingohr-Smith, Melissa, Fan, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192057/
https://www.ncbi.nlm.nih.gov/pubmed/28053550
http://dx.doi.org/10.2147/CEOR.S117200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192057/
https://www.ncbi.nlm.nih.gov/pubmed/28053550
http://dx.doi.org/10.2147/CEOR.S117200

Ejemplares similares